Durata Therapeutics Inc. is sending a message on the improving regulatory environment for anti-infectives at the Food & Drug Administration by what it is not telling Wall Street.
The company is not focusing on the hurdle posed by FDA approval for its second-generation IV lipoglycopeptide antibiotic, dalbavancin, and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?